Aligning Business, Corporate, and International Tax Strategy
Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company

How to Balance Internal and External Resources to Provide DMPK Support for Drug Discovery in China
Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China

Building an Integrated Biomedical Institute for Innovative Medicine in China
Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

Drug Discovery R&D in China: From Functional Capacity Outsourcing to Integrative  Partnership
Guoxin Zhu, Ph.D., CSO, Eli Lilly Asia, Inc., Shanghai Rep. Office

Accelerate Oncology Clinical Development in Asia
Michael Shi, Ph.D., Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis

The Latest Insights from China into Translational Research for Cancer
Jun Ren, M.D., Ph.D., Clinical Trials Coordination, Peking University School of Oncology/Beijing Cancer Hospital

Strategic Planning for Clinical Development Operations in China: Legal and Regulatory Considerations
Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.